Wendi Yajnik

Wendi Yajnik

Sanofi

Senior Director, R&D Transactions

Wendi is Senior Director at R&D Transactions in the department of Strategy, Science Policy & External Innovation at Sanofi. She is responsible for coordinating and negotiating various types of research agreements that focus on early discovery through external innovation with academic and corporate partners alike.  Prior to her current role, Wendi was Executive Director, Innovation, Partners Healthcare leading the business unit responsible for negotiating research collaborations with corporate partners and  identifying strategic and business opportunities for out-licensing intellectual property assets arising from basic science, clinical and IT related research activities at Partners’ hospitals, with particular emphasis on The Brigham and Women’s Hospital.  During her tenure at PHS, under Wendi’s leadership the licensing team spun out a large number of start-ups based on BWH technologies. A number of these start-ups were acquired by Pharma. To name a few,  Co-Stim, was acquired by Novartis, Provasculon, was acquired by Mesoblast, Tempero, was acquired by GSK, Syntonix, was acquired by Biogen, and Adheron, was acquired by Roche.  Before joining Partners, Wendi was an Assistant Professor of Medicine and Pathology at New York University School of Medicine. Wendi received her Ph.D. and M.S in Biology from the Graduate School of Arts and Science at New York University. She has a strong scientific background in the biological sciences and molecular endocrinology.  Wendi is also a co-inventor on US Patent 6,639,064 entitled, “NRIF3, novel co-activator for nuclear hormone receptors”, Issued on October 28, 2003.